Journal: Molecular medicine reports
Article Title: Tc-99m Ser-Asp-Val-Glu-Cys-Gly: A novel Tc-99m labeled hexapeptide for molecular and non-invasive tumor imaging.
PMID/MRN: 27748918
Publication Date: 2016-Nov-26
Abstract:
In a ProteoChip-based screening system and subsequent studies, serine-aspartic acid-valine (SDV) was demonstrated to specifically bind to integrin ?v?3. An SDV-containing peptide could target the tumor vessel and it may be an effective replacement for molecular imaging of the tumor. In the present study, a hexapeptide, SDV-glutamic acid-cysteine-glycine (ECG), was developed and evaluated its diagnostic performance as a tumor imaging agent in tumor-bearing mice. The hexapeptide SDV-ECG was synthesized using Fmoc solid-phase peptide synthesis. Following radiolabeling procedures with technetium-99m, the Tc-99m SDV-ECG complexes were prepared at high yields (>97%). The uptake of Tc-99m SDV-ECG within HT-1080 tumor cells (integrin ?v?3-positive) was confirmed by inÊvitro studies. ?-camera imaging revealed substantial uptake of Tc-99m SDV-ECG in the HT-1080 cell line tumor murine model. With the co-injection of excess SDV, tumoral uptake was blocked. Furthermore, HT-29 tumor cells (integrin ?v?3-negative) and inflammatory lesions demonstrated minimal uptake of Tc-99m SDV-ECG. In the present study, Tc-99m SDV-ECG was developed as a novel Tc-99m agent for tumor imaging. The current inÊvitro and inÊvivo studies demonstrated specific functions of Tc-99m SDV-ECG in tumor imaging.